It's interesting what ChatGPT puts forth about combining CORE-NK and Pomalidomide with Vactrosertib and its potential significance for solid tumours.
This is the area where CHM is being positioned within the immunotherapy space. Merck's patent for Keytruda runs out in 2028. The cost of treating the side effects of chemo is a real burden to economies. There is likely never going to be a blockbuster miracle cure for cancer but immunotherapy will give patients quality of life while being treated with the right combo of therapies.
- Forums
- ASX - By Stock
- CHM
- Ann: AML patient achieves Complete Response in CHM CORE-NK trial
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-57
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $100 | 25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 21874000 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 19510638 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 21874000 | 0.004 |
37 | 23631939 | 0.003 |
15 | 13500507 | 0.002 |
9 | 49600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 19510638 | 27 |
0.006 | 23500718 | 17 |
0.007 | 4700000 | 4 |
0.008 | 8542434 | 6 |
0.009 | 2767672 | 5 |
Last trade - 15.25pm 17/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online